Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

被引:16
|
作者
Lee, Dae Hyun [1 ,2 ]
Kumar, Abhishek [3 ]
Mohammed, Turab [4 ,5 ]
Peres, Lauren C. [6 ]
Alsina, Melissa [5 ]
Bachmeier, Christina
Blue, Brandon J. [5 ]
Brayer, Jason
Chandrasekhar, Sanjay [2 ]
Cruz, Ariel Grajales [5 ]
De Avila, Gabe
Elmariah, Hany [4 ]
Faramand, Rawan [4 ]
Freeman, Ciara [4 ]
Jain, Michael [4 ]
Khadka, Sushmita [4 ]
Khimani, Farhad [4 ]
Liu, Hien [4 ]
Nishihori, Taiga [4 ]
Oswald, Laura B. [1 ,7 ]
Puglianini, Omar A. Castaneda [4 ]
Shain, Kenneth H. [5 ]
Smith, Eric [4 ]
Baz, Rachid C. [5 ]
Locke, Frederick L. [4 ]
Oliveira, Guilherme H. [1 ,2 ]
Alomar, Mohammed [1 ,2 ]
Hansen, Doris K. [4 ]
机构
[1] Univ South Florida Morsani, Coll Med, Div Cardiovasc Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Cardiooncol, Tampa, FL USA
[3] Univ South Florida Morsani, Dept Internal Med, Coll Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunoth, Tampa, FL 33612 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
关键词
T-CELL THERAPY; CARDIOVASCULAR EVENTS; ADULTS;
D O I
10.1182/bloodadvances.2023009766
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, & lambda; light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (& GE;grade 2) cytokine release syndrome (CRS) and immune cell-associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.
引用
收藏
页码:4247 / 4257
页数:11
相关论文
共 50 条
  • [1] Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
    Logue, Jennifer M.
    Peres, Lauren C.
    Hashmi, Hamza
    Colin-Leitzinger, Christelle M.
    Shrewsbury, Alexandria M.
    Hosoya, Hitomi
    Gonzalez, Rebecca M.
    Copponex, Christina
    Kottra, Krista H.
    Hovanky, Vanna
    Sahaf, Bita
    Patil, Sunita
    Lazaryan, Aleksandr
    Jain, Michael D.
    Baluch, Aliyah
    Klinkova, Olga V.
    Bejanyan, Nelli
    Faramand, Rawan G.
    Elmariah, Hany
    Khimani, Farhad
    Davila, Marco L.
    Mishra, Asmita
    Blue, Brandon J.
    Grajales-Cruz, Ariel F.
    Puglianini, Omar A. Castaneda
    Liu, Hien D.
    Nishihori, Taiga
    Freeman, Ciara L.
    Brayer, Jason B.
    Shain, Kenneth H.
    Baz, Rachid C.
    Locke, Frederick L.
    Alsina, Melissa
    Sidana, Surbhi
    Hansen, Doris K.
    BLOOD ADVANCES, 2022, 6 (24) : 6109 - 6119
  • [2] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Madduri, Deepu
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Lin, Yi
    Siegel, David
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Cavo, Michele
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Rambaldi, Alessandro
    Reece, Donna
    Petrocca, Fabio
    Massaro, Monica
    Connarn, Jamie N.
    Kaiser, Shari
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08): : 705 - 716
  • [3] FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
    Sharma, Poornima
    Kanapuru, Bindu
    George, Bindu
    Lin, Xue
    Xu, Zhenzhen
    Bryan, Wilson W.
    Pazdur, Richard
    Theoret, Marc R.
    CLINICAL CANCER RESEARCH, 2022, 28 (09) : 1759 - 1764
  • [4] Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances
    Tu, Wei
    Xiao, Yajuan
    Wang, Yadong
    Luo, Rongcheng
    Chen, Zhe-Sheng
    DRUGS OF TODAY, 2022, 58 (03) : 117 - 132
  • [5] Idecabtagene Vicleucel in Relapsed Myeloma
    Kidoguchi, Keisuke
    Mori, Jinichi
    Tanimoto, Tetsuya
    Quintas-Cardama, Alfonso
    Munshi, Nikhil C.
    Hege, Kristen
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (24): : 2356 - 2357
  • [6] Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
    Little, Jessica S.
    Shah, Parth
    Sperling, Adam S.
    Branagan, Andrew R.
    Nadeem, Omar
    Yee, Andrew J.
    Raje, Noopur S.
    Munshi, Nikhil C.
    Hammond, Sarah
    BLOOD, 2021, 138 : 3839 - +
  • [7] A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma
    Hansen, Doris
    Peres, Lauren
    Dima, Danai
    Richards, Alicia
    Shune, Leyla
    Afrough, Aimaz
    Midha, Shonali
    Dhakal, Binod
    Kocoglu, Mehmet H.
    Ferreri, Christopher
    Davis, James
    Herr, Megan
    Forsberg, Peter
    Janakiram, Murali
    Reshef, Ran
    Sborov, Douglas W.
    Khouri, Jack
    Richard, Shambavi
    Martin, Thomas
    Lin, Yi
    Patel, Krina
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S5 - S5
  • [8] Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
    Delforge, Michel
    Shah, Nina
    Miguel, Jesus San F.
    Braverman, Julia
    Dhanda, Devender S.
    Shi, Ling
    Guo, Shien
    Yu, Peiwen
    Liao, Weiqin
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD ADVANCES, 2022, 6 (04) : 1309 - 1318
  • [9] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
    Melody, Megan
    Przybylski, Daniel
    Robinson, Adam
    Lin, Adam
    Gordon, Leo
    Adekola, Kehinde
    Singhal, Seema
    Mehta, Jayesh
    Moreira, Jonathan
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
  • [10] Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
    Merz, Maximilian
    Albici, Anca-Maria
    von Tresckow, Bastian
    Rathje, Kristin
    Fenk, Roland
    Holderried, Tobias
    Mueller, Fabian
    Tovar, Natalia
    Oliver-Caldes, Aina
    Vucinic, Vladan
    Kharboutli, Soraya
    Baermann, Ben-Niklas
    Ayuk, Francis
    Platzbecker, Uwe
    Stoelzel, Friedrich
    Schub, Nathalie
    Schmitz, Friederike
    Fandrei, David
    Born, Patrick
    Khandanpour, Cyrus
    Hanoun, Christine
    Hoerster, Keven
    Teichert, Marcel
    Jeker, Barbara
    Hoffmann, Michele
    Kroeger, Nicolaus
    de Larrea, Carlos Fernandez
    Pabst, Thomas
    Gagelmann, Nico
    HEMASPHERE, 2025, 9 (01):